Skip to main content

Table 7 Progression-free survival (PFS) and overall survival (OS)

From: Prospective, open, multi-centre phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and oxaliplatin in patients with adenocarcinoma of the oesophagogastric junction

  Dose level  
  1 2 3 Total
Number of patients 4 (100%) 13 (100%) 7 (100%) 24 (100%)
PFS (months)     
  Median (95% CI) 2.25 (1.4, 8.1) 6.5 (2.5, n.a.) 13.5 (2.3, 14.4) 6.5 (2.3, 13.3)
OS (months)     
  Median (95% CI) 8.5 (5.6, 12.0) 29.5 (4.8, n.a.) 22.1 (16.3, 22.1) 16.3 (7.6, 29.5)